AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - A 5-YEAR SINGLE-CENTER EXPERIENCE

被引：5

作者：

AGER, S ^{[1
]}

WIMPERIS, JZ ^{[1
]}

TOLLIDAY, B ^{[1
]}

JESTICE, K ^{[1
]}

BASS, G ^{[1
]}

BAGLIN, T ^{[1
]}

MARCUS, RE ^{[1
]}

机构：

[1] ADDENBROOKES HOSP,DEPT HAEMATOL,BONE MARROW TRANSPLANT UNIT,CAMBRIDGE CB2 2QQ,ENGLAND

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 3-4期

关键词：

ABMT; HODGKINS DISEASE; RELAPSED; REFRACTORY;

D O I：

10.3109/10428199409056290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results from 40 patients who have undergone autologous bone marrow transplantation (ABMT) for relapsed or refractory Hodgkin's disease between March 1988 and September 1992 have been analysed. In contrast to our results in patients with relapsed HD, our results in patients with refractory HD are comparatively poor. Conventional salvage chemotherapy also seems inappropriate in these patients and we therefore believe they should be offered high-dose chemotherapy before their disease becomes refractory to conventionally scheduled regimens. Peripheral blood stem cell (PBSC) transplant now offers an attractive alternative to ABMT and may replace both intensive salvage chemotherapy and ABMT as the optimum treatment for patients who fail to respond to conventional chemotherapy regimens.

引用

页码：263 / 272

页数：10

共 39 条

[31] Jagannath S., Armitage J.O., Dicke K.A., Prognostic Factors for response and survival after High-Dose Cyclophosphamide, Carmustine, and Etoposide with Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease, J. Clin. Oncol., 7, Suppl. 2, pp. 179-185, (1989)
[32] Straus D.J., Gaynor J.J., Myers J., Prog-nostic Factors Among 185 Adults with Newly Diagnosed Advanced Hodgkin's Disease Treated with Alternating Potentially Noncross-Resistant Chemotherapy and Intermediate-Dose Radiation Therapy, J. Clin. Oncol., 8, Suppl. 7, pp. 1173-1186, (1990)
[33] Carde P., MacKintosh F.R., Rosenberg S.A., A dose and time response analysis of Treatment of Hodgkin's Disease with MOPP chemotherapy, J. Clin. Oncol., 1, pp. 146-153, (1983)
[34] Prosnitz L.R., Farber L.R., Kapp D.S., Combined modality therapy for advanced Hodgkin's Disease: 15-year follow-up data, J. Clin. Oncol., 6, pp. 603-612, (1988)
[35] Pfreundschuh M.G., Rueffer U., Lathan B., DEXA-BEAM in patients with Hodgkin's Disease refractory to multi-drug chemotherapy regimens: A multicentre trial of the German Hodgkin's Study Group, (1993)
[36] Korbling M., Dorken B., Ho A.D., Autolo-gous Transplantation of Blood-Derived Haemopoietic Stem Cells After Myeloablative Therapy in a Patient with Burkitt's Lymphoma, Blood, 67, Suppl. 2, pp. 529-532, (1986)
[37] Kessinger A., Armitage J.O., The evolving role of autologous Peripheral Stem Cell Transplant following high-dose therapy for malignancies, Blood, 77, pp. 211-213, (1991)
[38] Hardingham J.E., Kotasek D., Sage R.E., Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation, Bone Marrow Transplant., 11, pp. 15-20, (1993)
[39] Carella A.M., Carlier P., Congui A., Autologous Bone Marrow Transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol, Bone Marrow Transplant., 8, pp. 99-103, (1991)

← 1 2 3 4 →